RecruitingPhase 3NCT04293562
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
Sponsor: Children's Oncology Group
Albany, NY · Brooklyn, NY · Buffalo, NY · +183 more sites